October 2013 Life Science Industry Research Reports

Frontier Pharma – Rheumatoid Arthritis: Identifying and Commercializing First-in-Class Innovation

Published in Oct 2013 ; US $ 3500 Onwards; Publisher: GBI Research

GBI Research has released a new pharmaceutical report, “Frontier Pharma: Rheumatoid Arthritis Identifying and Commercializing First-in-Class Innovation”. This highly competitive market is saturated with multiple targeted monoclonal Antibody (mAb) therapies and small molecules, yet more of these treatments are expected […]

Oblean (Obesity) – Forecast and Market Analysis to 2022

Published in Oct 2013 ; US $ 3495 Onwards; Publisher: GlobalData

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple […]

Xenical (Obesity) – Forecast and Market Analysis to 2022

Published in Oct 2013 ; US $ 3495 Onwards; Publisher: GlobalData

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple […]

Empatic (Obesity) – Forecast and Market Analysis to 2022

Published in Oct 2013 ; US $ 3495 Onwards; Publisher: GlobalData

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple […]

Contrave (Obesity) – Forecast and Market Analysis to 2022

Published in Oct 2013 ; US $ 3495 Onwards; Publisher: GlobalData

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple […]

Victoza (Obesity) – Forecast and Market Analysis to 2022

Published in Oct 2013 ; US $ 3495 Onwards; Publisher: GlobalData

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple […]

Belviq (Obesity) – Forecast and Market Analysis to 2022

Published in Oct 2013 ; US $ 3495 Onwards; Publisher: GlobalData

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple […]

Qsymia (Obesity) – Forecast and Market Analysis to 2022

Published in Oct 2013 ; US $ 3495 Onwards; Publisher: GlobalData

After a more than decade-long dormancy, the obesity market is undergoing a revival with the advent of several novel therapies that will lend considerable visibility to this indication space. This includes the use of combination therapies that simultaneously target multiple […]